Hill-Rom (NYSE:HRC) was downgraded by Zacks Investment Research from a “buy” rating to a “sell” rating in a research note issued to investors on Thursday, April 12th.
According to Zacks, “Hill-Rom has outperformed its industry in a year's time. However, a decline in revenues at the company's Patient Support Systems segment is quite disappointing. Also, foreign exchange and a tough competitive landscape remain headwinds. On a positive note, of late the company has been seeing solid year-over-year increase in revenues on strong international growth primarily banking on the 'One Hill-Rom' approach. The company is focusing on product innovation, the latest one being Connex Cardio ECG. Hill-Rom has updated its 2020 long-range financial objectives and outlook considering gains from the new tax reform. Hill-Rom now expects to drive adjusted earnings by 12-14% on a compound annual basis through 2020, compared with the previous guidance of 10-12%. Moreover, an improvement in gross and adjusted operating margin buoys optimism.”
A number of other equities analysts have also weighed in on HRC. KeyCorp reaffirmed a “buy” rating and issued a $94.00 target price on shares of Hill-Rom in a research note on Thursday, December 21st. Morgan Stanley lowered shares of Hill-Rom from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, January 2nd. They noted that the move was a valuation call. Raymond James raised shares of Hill-Rom from a “market perform” rating to an “outperform” rating and set a $94.00 target price for the company in a research note on Wednesday, January 3rd. Barclays reaffirmed a “buy” rating and issued a $100.00 target price on shares of Hill-Rom in a research note on Wednesday, January 10th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $105.00 target price (up from $90.00) on shares of Hill-Rom in a research note on Tuesday, January 16th. One research analyst has rated the stock with a sell rating, five have given a hold rating and six have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $93.89.
Hill-Rom (NYSE:HRC) last announced its quarterly earnings results on Friday, January 26th. The medical technology company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.13. Hill-Rom had a net margin of 7.14% and a return on equity of 20.24%. The company had revenue of $669.70 million during the quarter, compared to analyst estimates of $670.00 million. During the same quarter in the previous year, the business earned $0.75 EPS. The firm’s revenue was up 5.1% on a year-over-year basis. equities analysts expect that Hill-Rom will post 4.62 EPS for the current fiscal year.
In other Hill-Rom news, SVP Deborah Rasin sold 7,590 shares of the business’s stock in a transaction dated Thursday, April 12th. The shares were sold at an average price of $86.02, for a total transaction of $652,891.80. Following the sale, the senior vice president now directly owns 14,028 shares of the company’s stock, valued at approximately $1,206,688.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 1.90% of the company’s stock.
A number of large investors have recently modified their holdings of HRC. We Are One Seven LLC bought a new stake in Hill-Rom during the 4th quarter worth about $188,000. CAPROCK Group Inc. bought a new stake in shares of Hill-Rom in the 4th quarter valued at about $211,000. Braun Stacey Associates Inc. bought a new stake in shares of Hill-Rom in the 4th quarter valued at about $233,000. BancorpSouth Bank bought a new stake in shares of Hill-Rom in the 4th quarter valued at about $241,000. Finally, Atria Investments LLC bought a new stake in shares of Hill-Rom in the 4th quarter valued at about $262,000. 82.49% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Hill-Rom (HRC) Cut to Sell at Zacks Investment Research” was originally posted by Week Herald and is the sole property of of Week Herald. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://weekherald.com/2018/04/21/hill-rom-hrc-stock-rating-lowered-by-zacks-investment-research.html.
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It provides medical surgical beds, intensive care unit beds, bariatric patient beds, lifts and other devices, non-invasive therapeutic products and surfaces, and communications technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.